The six-month data on Cabtreo (clindamycin phosphate 1.2%, adapalene 0.15%, benzoyl peroxide (BPO) 3.1%) is in, and the triple-combination topical gel continues to produce meaningful improvements in acne.
Ortho Dermatologics’ Cabtreo demonstrated significant and continued improvements in acne lesions, scarring, Post-Inflammatory Hyperpigmentation (PIH), Post-Inflammatory Erythema (PIE) , and quality of life across 24 weeks of once-daily treatment, according to new data shared at the 2025 Annual Meeting of the American Academy of Dermatology.
Approximately two-thirds of participants achieved treatment success. At week 24, there was an 89% reduction from baseline in inflammatory lesions and a 70% reduction in noninflammatory lesions, the study showed. There were significant reductions from baseline in facial scarring and PIH by weeks 12 and 8, respectively. Moreover, the gel was well tolerated, and no adverse events/experiences occurred in this single-center study.
The bottom line? “Cabtreo is appropriate for long-term topical treatment of acne vulgaris,” the researchers conclude.
